Core Viewpoint - Fortrea, a leading global contract research organization, is set to present at the J.P. Morgan Annual Healthcare Conference on January 13, 2026, at 11:15 am PST, highlighting its role in the life sciences industry [1]. Company Overview - Fortrea (Nasdaq: FTRE) specializes in providing clinical development solutions to the life sciences sector, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to enhance healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over 30 years of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a strong investigator site network and a commitment to delivering agile solutions to its clients [3].

Group 1 - Fortrea, a leading global contract research organization (CRO), will participate in the J.P. Morgan Annual Healthcare Conference on January 13, 2025, at 5:15 pm PST [1] - The conference will include a presentation and Q&A session, with a live webcast available on Fortrea's Investor Relations website [1] - Investors interested in one-on-one meetings are encouraged to contact their banking representatives [1] Group 2 - Fortrea specializes in clinical development solutions for the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [2] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [2] - Fortrea operates in approximately 100 countries, providing focused and agile solutions to its global customers [2]

Group 1: Artisan Mid Cap Value Fund Performance - Artisan Mid Cap Value Fund's Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97% in Q3 2025, compared to a 6.18% return for the Russell Midcap Value Index [1] - The equity markets continued to rally in Q3 2025, driven by strong corporate earnings, rising AI capital expenditures, and expectations for economic support from US fiscal policy and lower interest rates [1] Group 2: ICON Public Limited Company Overview - ICON Public Limited Company (NASDAQ:ICLR) is the second-largest global contract research organization (CRO), providing outsourced clinical development services to the pharmaceutical and biotechnology industries [3] - The one-month return for ICON was 3.61%, while its shares lost 12.45% over the last 52 weeks, closing at $188.67 per share on January 2, 2026, with a market capitalization of $14.673 billion [2] Group 3: Market Conditions and Outlook for ICON - The life sciences, pharma, and biotech sectors have faced weakness over the past year, but positive earnings reports from ICON and other CROs suggest that biopharma demand may be bottoming [3] - The biopharma funding environment has been challenging due to higher interest rates and macroeconomic uncertainty, leading to cautious decision-making among pharma and biotech companies [3] - The current market conditions present an opportunity to build a position in ICON, which is expected to generate mid- to high-single-digit revenue growth in a normalized environment and gain market share in a fragmented industry [3] - ICON is trading at just 13X forward earnings, near its cheapest levels since the 2008–2009 global financial crisis, making the risk/reward profile attractive [3]

Core Insights - Charles River Laboratories International, Inc. (CRL) is a leading American contract research organization (CRO) with a market cap of $9.5 billion, serving various sectors including pharmaceuticals and biotechnology [1] - CRL is categorized as a mid-cap stock, benefiting from strong competitive advantages such as end-to-end preclinical drug development capabilities and long-standing client relationships [2] - The stock has shown significant short-term performance, gaining 30.2% over the past three months, outperforming the Dow Jones Industrial Average [3] Performance Metrics - CRL reached a 52-week high of $200.58, but on a year-to-date basis, it is up only 7.3%, lagging behind the Dow's 13.8% rise in 2025 [3][4] - The stock has maintained a position above its 50-day and 200-day moving averages since late September, indicating a strengthening technical uptrend [4] - Following an upgrade from JPMorgan Chase & Co., CRL shares gained over 2%, with the price target raised to $190, reflecting optimism about the company's fundamentals [5] Competitive Position - Compared to its peer Labcorp Holdings Inc., CRL has underperformed, with Labcorp showing a 14.8% increase year-to-date and 13.5% over the past 52 weeks [6]

Core Insights - Wasatch Global Investors reported a decline of -3.17% for its fund-Investor Class in Q3 2025, underperforming the Russell 2000 Growth Index which gained 12.19% during the same period [1] - The strong performance of US small-cap equities was supported by the Federal Reserve's interest rate cut [1] Company Performance - Medpace Holdings, Inc. (NASDAQ:MEDP) was highlighted as the top contributor to the fund's performance, with a one-month return of -4.76% and a 52-week gain of 59.52% [2][3] - Medpace reported revenue of $659.9 million in Q3 2025, marking a year-over-year increase of 23.7% [4] - The company raised its full-year guidance following strong revenue and earnings growth, despite a slowdown in the biotech funding cycle [3] Market Position - Medpace Holdings, Inc. had a market capitalization of $15.715 billion as of December 12, 2025, with shares closing at $557.90 [2] - The number of hedge funds holding Medpace increased from 42 to 43 in the third quarter [4] - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, and certain AI stocks are considered to offer greater upside potential [4]

Core Insights - Inotiv, Inc. has announced a strategic collaboration with VUGENE to enhance AI-assisted drug discovery and improve data-driven insights across the drug development continuum [1][2]. Company Overview - Inotiv, Inc. is a leading Contract Research Organization (CRO) that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [1][4]. - The company focuses on increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market [4]. Collaboration Details - The partnership will integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, facilitating more efficient analysis of complex biological data [2][3]. - This collaboration aims to enhance Inotiv's capabilities in interpreting various molecular datasets, ultimately improving predictions of drug efficacy and safety during early-stage research [2][3]. Strategic Goals - The collaboration is expected to enable clients to make faster and more informed decisions by leveraging VUGENE's AI-enabled bioinformatics platform [3]. - The partnership represents an opportunity for VUGENE to expand the application of its computational technologies in real-world research environments [3][5]. Technological Integration - VUGENE's platform integrates biological data from multiple sources, including (epi)genomics, transcriptomics, proteomics, and metabolomics, to elucidate disease mechanisms and therapeutic modes of action [5].

Core Insights - Polen Capital's "Polen International Growth Strategy" reported a return of -4.23% gross and -4.53% net of fees in Q3 2025, underperforming the MSCI ACWI (ex-USA) which gained 6.89% [1] - The strategy's concentrated quality investing approach did not yield expected results during the quarter [1] Company Performance - ICON Public Limited Company (NASDAQ:ICLR) was highlighted as a top contributor to the portfolio's performance, with a one-month return of 11.43% despite a 15.68% decline over the past 52 weeks [2][3] - ICON's stock closed at $182.10 on December 08, 2025, with a market capitalization of $14.162 billion [2] - The company reported Q3 2025 revenue of $2.043 billion, reflecting a year-on-year increase of 0.6% [4] Investment Outlook - Polen Capital believes that ICON is positioned for recovery and steady, low double-digit EPS growth, viewing it as a best-in-class operator in its sector [3] - Despite ICON's potential, the analysis suggests that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Insights - SCTbio and Fortrea have announced a strategic collaboration to enhance the development and delivery of advanced therapies, aiming to streamline processes and accelerate timelines for bringing therapies to patients [1][2][3] Company Overview - SCTbio is a leading Contract Development and Manufacturing Organization (CDMO) with over 15 years of experience in GMP manufacturing for Advanced Therapy Medicinal Products (ATMPs), providing end-to-end services including apheresis materials, vector production, and quality control [4] - Fortrea is a global provider of clinical development solutions, partnering with biopharmaceutical and biotechnology companies to drive healthcare innovation across various therapeutic areas, leveraging three decades of experience [6] Collaboration Details - The partnership aims to create synchronized solutions that de-risk programs, streamline planning, and optimize cost-efficiency throughout the development lifecycle, addressing over 4,400 gene, cell, and RNA therapies currently in development [2][3] - By combining Fortrea's clinical reach with SCTbio's manufacturing expertise, the collaboration seeks to enhance protocol design, supply chain resilience, and the delivery of therapies globally [3] - The collaboration will align clinical trial logistics with GMP manufacturing readiness, ensuring synchronized planning and execution for cell and gene therapy programs [3]

Core Insights - Inotiv, Inc. reported a 5.9% increase in revenue for Q4 FY 2025, reaching $138.1 million, and a 4.5% increase for FY 2025, totaling $513.0 million [1][12] - The operating loss for Q4 FY 2025 decreased by 48.5% to $6.8 million, while the annual operating loss for FY 2025 decreased by 64.2% to $30.9 million [1][6] Financial Performance - Q4 FY 2025 revenue was $138.1 million, up from $130.4 million in Q4 FY 2024, driven by a $7.1 million increase in DSA revenue and a $0.7 million increase in RMS revenue [7][10] - FY 2025 revenue increased to $513.0 million from $490.7 million in FY 2024, with RMS revenue up by $14.5 million and DSA revenue up by $7.8 million [12][13] - Consolidated net loss for Q4 FY 2025 was $8.6 million, or 6.2% of total revenue, compared to a loss of $18.9 million, or 14.5% of total revenue, in Q4 FY 2024 [7][10] - Adjusted EBITDA for Q4 FY 2025 was $11.8 million, or 8.5% of total revenue, compared to $5.4 million, or 4.1% of total revenue, in Q4 FY 2024 [7][10] Segment Performance - DSA revenue for Q4 FY 2025 was $51.6 million, a 15.7% increase from $44.6 million in Q4 FY 2024, while RMS revenue was $86.5 million, a slight increase of 0.8% from $85.8 million [2][32] - For FY 2025, DSA revenue totaled $187.9 million, up 4.3% from $180.1 million in FY 2024, and RMS revenue reached $325.1 million, a 4.7% increase from $310.6 million [2][12] Operational Highlights - The book-to-bill ratio for Q4 FY 2025 was 1.08x for the DSA services business, indicating strong demand [7] - DSA backlog increased to $138.2 million at September 30, 2025, up from $129.9 million at the same time last year [7] Management Commentary - The CEO emphasized the focus on improving cash flow, margins, and client metrics, noting that the revenue increase was in line with expectations [3][4] - The company remains committed to client satisfaction and delivering high-quality products and services, with a significant increase in DSA net awards by approximately 61% year-over-year [4]

Core Insights - Fortrea, a leading global contract research organization (CRO), is actively participating in key healthcare conferences in December 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Company Overview - Fortrea (Nasdaq: FTRE) provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over three decades of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a diverse and talented team to deliver agile solutions globally [3].